Y Intercept Hong Kong Ltd Boosts Holdings in argenex SE $ARGX

Y Intercept Hong Kong Ltd grew its position in argenex SE (NASDAQ:ARGX) by 41.1% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 5,884 shares of the company’s stock after acquiring an additional 1,714 shares during the quarter. Y Intercept Hong Kong Ltd’s holdings in argenex were worth $4,297,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. M&T Bank Corp lifted its stake in shares of argenex by 20,977.7% during the 4th quarter. M&T Bank Corp now owns 778,610 shares of the company’s stock worth $654,772,000 after acquiring an additional 774,916 shares during the last quarter. Sands Capital Management LLC boosted its stake in shares of argenex by 2,046.6% during the fourth quarter. Sands Capital Management LLC now owns 356,870 shares of the company’s stock valued at $300,110,000 after purchasing an additional 340,245 shares during the period. Invesco Ltd. lifted its holdings in argenex by 390.4% during the 4th quarter. Invesco Ltd. now owns 416,408 shares of the company’s stock valued at $350,178,000 after buying an additional 331,489 shares in the last quarter. Wellington Management Group LLP increased its position in shares of argenex by 80.1% during the third quarter. Wellington Management Group LLP now owns 729,986 shares of the company’s stock worth $538,408,000 after acquiring an additional 324,653 shares during the period. Finally, Two Sigma Investments LP boosted its holdings in shares of argenex by 570.3% in the third quarter. Two Sigma Investments LP now owns 294,160 shares of the company’s stock valued at $216,961,000 after purchasing an additional 250,278 shares during the period. Institutional investors own 60.32% of the company’s stock.

Analysts Set New Price Targets

Several analysts recently weighed in on ARGX shares. Glj Research upgraded argenex to a “strong-buy” rating in a report on Friday, April 3rd. Morgan Stanley increased their target price on shares of argenex from $1,170.00 to $1,180.00 and gave the company an “overweight” rating in a research report on Wednesday, June 24th. Oppenheimer reduced their price target on argenex from $1,060.00 to $1,014.00 and set an “outperform” rating on the stock in a research report on Thursday, April 2nd. Weiss Ratings reaffirmed a “hold (c)” rating on shares of argenex in a research report on Monday, April 20th. Finally, Wall Street Zen downgraded argenex from a “buy” rating to a “hold” rating in a report on Sunday, March 8th. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat, argenex presently has an average rating of “Moderate Buy” and a consensus target price of $1,034.56.

argenex Price Performance

argenex stock opened at $939.68 on Monday. argenex SE has a 52 week low of $536.02 and a 52 week high of $953.58. The stock has a 50-day moving average price of $840.98 and a 200 day moving average price of $810.88. The company has a market capitalization of $58.44 billion, a price-to-earnings ratio of 41.84, a price-to-earnings-growth ratio of 1.16 and a beta of 0.45.

argenex (NASDAQ:ARGX) last released its quarterly earnings data on Tuesday, March 31st. The company reported $5.52 earnings per share for the quarter. The firm had revenue of $1.31 billion for the quarter. argenex had a net margin of 31.31% and a return on equity of 44.37%. Research analysts anticipate that argenex SE will post 26.27 EPS for the current fiscal year.

argenex Company Profile

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.